{"entity":{"id":"triptolide-payloads","kind":"term","name":"Triptolide payloads","aka":["TFIIH inhibitor payloads","Y-TR1","Y-TR-1"],"tldr":"Triptolide payloads interfere with the cell's ability to make messages from its genes. An antibody-linked version has been studied in cancer cells and mice.","summary":"Y-TR1 combines the CD26-directed antibody YS110 with a triptolide derivative that inhibits the general transcription factor TFIIH. The published study reported altered RNA synthesis and antitumor activity in CD26-positive experimental models. This is preclinical evidence for a transcription-directed conjugate, not evidence that triptolide is an established antibody payload in clinical care.","asOf":"2026-11-08","links":[{"label":"Hayashi et al., Y-TR1 transcription-inhibitor conjugate (2019)","url":"https://doi.org/10.3390/cancers11081138"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload","transcription-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/triptolide-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"transcription-inhibitor-payloads","kind":"term","name":"Transcription-inhibitor payloads","route":"/terms/transcription-inhibitor-payloads/"}]}}